Secretome Therapeutics Secures $30M, Propels Duchenne Cardiomyopathy Therapy
June 1, 2026, 9:39 am
Secretome Therapeutics closed a $30 million Series A round led by RA Capital. This pivotal funding advances STM-01, an innovative therapy for Duchenne muscular dystrophy-associated cardiomyopathy. The nCPC-derived candidate targets inflammation and fibrosis. It supports myocardial function. The Plano-based biotech aims for Phase 2/3 trials. David Lubner joined the board. Matthew Hammond became an observer. The investment validates Secretome's science. It underscores a commitment to rare cardiac disease. Future therapies for heart failure are also in development, marking a significant stride in regenerative medicine.
Plano, Texas – Secretome Therapeutics announced a significant financial milestone. The clinical-stage biotechnology firm secured $30 million in Series A funding. RA Capital Management led the round. This investment marks a crucial moment for the company. It propels their lead therapy, STM-01.
STM-01 targets Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM). This condition represents a severe, life-limiting complication of Duchenne muscular dystrophy (DMD). Current treatment options are limited. Patients face progressive heart decline. Secretome aims to change this outlook.
The company develops therapies from neonatal cardiac progenitor cells (nCPC). This novel approach leverages the regenerative potential of these cells. nCPC-derived treatments offer a unique mechanism. They modulate inflammatory and fibrotic pathways. They also support myocardial function. This dual action is vital for cardiac repair.
Funding will expedite STM-01's clinical journey. Secretome plans pivotal Phase 2 and Phase 3 trials. These studies are critical steps. They move the therapy closer to patient access. The proceeds will also bolster company operations. A robust operational foundation is essential for rapid development.
DMD-CM is a devastating disease. It lacks effective disease-modifying options. STM-01 offers new hope. It is designed as a cellular therapy. The goal is to improve cardiac health in DMD patients. Success would redefine care standards. It would extend and improve lives.
The Series A funding validates Secretome’s scientific platform. It affirms their clinical development strategy. RA Capital’s investment highlights the potential of nCPC-based therapeutics. The sector watches these advancements closely. Regenerative medicine continues its growth.
Key leadership changes accompany this financial boost. David Lubner joined Secretome’s Board of Directors. Lubner brings over 25 years of life sciences experience. His background includes executive roles at major biotech firms. He offers deep financial and operational expertise. His guidance will be invaluable.
Matthew Hammond, a Partner at RA Capital Management, joined as a Board Observer. His strategic insight strengthens the company’s vision. Dr. Charles Edwards stepped down from the board. His contributions during Secretome’s formative years were significant. The company moves forward with renewed leadership.
Lubner's past roles include CFO at Ra Pharmaceuticals and Tetraphase Pharmaceuticals. He also served at PharMetrics and ProScript. He currently serves on other biotech boards. His extensive network and experience are strategic assets. They will help navigate complex clinical and market landscapes.
Secretome is not solely focused on STM-01. The company advances STM-21. This secretome-based therapeutic is in preclinical development. It represents another facet of their innovative pipeline. Secretome explores additional nCPC-based therapies. These target various cardiac diseases. Heart failure indications are a primary focus.
The scope of Secretome’s work extends beyond rare diseases. Their nCPC platform holds broader promise. It could address other cardiomyopathies. This includes dilated cardiomyopathy. It also encompasses heart failure with preserved ejection fraction (HFpEF). These conditions affect millions worldwide.
The biotech firm aims to establish itself as a leader. It focuses on immunology and inflammation (I&I) in cardiac disease. Their progenitor cell-based therapeutics are at the forefront. This positions Secretome for significant impact. It enters a transformative period of growth.
The investment reflects confidence in Secretome’s team. It supports their scientific rigor. The market for innovative cardiac therapies is substantial. Unmet needs persist across many heart conditions. Secretome is stepping into this gap.
Advancing STM-01 rapidly is a core objective. The company envisions STM-01 as a potential "gold standard" therapy. This ambition drives their development efforts. Patients and families affected by DMD await better options. Secretome offers tangible hope.
This funding ensures the resources necessary for rigorous clinical trials. It allows for expanding research. It supports future pipeline candidates. The company’s trajectory is set. It aims to deliver breakthrough cardiac treatments.
Secretome Therapeutics embodies cutting-edge biotechnology. Its nCPC platform represents a novel therapeutic modality. It targets complex biological pathways. Inflammation, fibrosis, and myocardial function are key. Addressing these simultaneously is critical for cardiac repair.
The future looks bright for Secretome Therapeutics. Their $30 million Series A funding provides substantial momentum. It paves the way for advanced clinical development. It strengthens their leadership. It reinforces their commitment to patients. Secretome is poised to make a profound difference in cardiac medicine.
Plano, Texas – Secretome Therapeutics announced a significant financial milestone. The clinical-stage biotechnology firm secured $30 million in Series A funding. RA Capital Management led the round. This investment marks a crucial moment for the company. It propels their lead therapy, STM-01.
STM-01 targets Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM). This condition represents a severe, life-limiting complication of Duchenne muscular dystrophy (DMD). Current treatment options are limited. Patients face progressive heart decline. Secretome aims to change this outlook.
The company develops therapies from neonatal cardiac progenitor cells (nCPC). This novel approach leverages the regenerative potential of these cells. nCPC-derived treatments offer a unique mechanism. They modulate inflammatory and fibrotic pathways. They also support myocardial function. This dual action is vital for cardiac repair.
Funding will expedite STM-01's clinical journey. Secretome plans pivotal Phase 2 and Phase 3 trials. These studies are critical steps. They move the therapy closer to patient access. The proceeds will also bolster company operations. A robust operational foundation is essential for rapid development.
DMD-CM is a devastating disease. It lacks effective disease-modifying options. STM-01 offers new hope. It is designed as a cellular therapy. The goal is to improve cardiac health in DMD patients. Success would redefine care standards. It would extend and improve lives.
The Series A funding validates Secretome’s scientific platform. It affirms their clinical development strategy. RA Capital’s investment highlights the potential of nCPC-based therapeutics. The sector watches these advancements closely. Regenerative medicine continues its growth.
Key leadership changes accompany this financial boost. David Lubner joined Secretome’s Board of Directors. Lubner brings over 25 years of life sciences experience. His background includes executive roles at major biotech firms. He offers deep financial and operational expertise. His guidance will be invaluable.
Matthew Hammond, a Partner at RA Capital Management, joined as a Board Observer. His strategic insight strengthens the company’s vision. Dr. Charles Edwards stepped down from the board. His contributions during Secretome’s formative years were significant. The company moves forward with renewed leadership.
Lubner's past roles include CFO at Ra Pharmaceuticals and Tetraphase Pharmaceuticals. He also served at PharMetrics and ProScript. He currently serves on other biotech boards. His extensive network and experience are strategic assets. They will help navigate complex clinical and market landscapes.
Secretome is not solely focused on STM-01. The company advances STM-21. This secretome-based therapeutic is in preclinical development. It represents another facet of their innovative pipeline. Secretome explores additional nCPC-based therapies. These target various cardiac diseases. Heart failure indications are a primary focus.
The scope of Secretome’s work extends beyond rare diseases. Their nCPC platform holds broader promise. It could address other cardiomyopathies. This includes dilated cardiomyopathy. It also encompasses heart failure with preserved ejection fraction (HFpEF). These conditions affect millions worldwide.
The biotech firm aims to establish itself as a leader. It focuses on immunology and inflammation (I&I) in cardiac disease. Their progenitor cell-based therapeutics are at the forefront. This positions Secretome for significant impact. It enters a transformative period of growth.
The investment reflects confidence in Secretome’s team. It supports their scientific rigor. The market for innovative cardiac therapies is substantial. Unmet needs persist across many heart conditions. Secretome is stepping into this gap.
Advancing STM-01 rapidly is a core objective. The company envisions STM-01 as a potential "gold standard" therapy. This ambition drives their development efforts. Patients and families affected by DMD await better options. Secretome offers tangible hope.
This funding ensures the resources necessary for rigorous clinical trials. It allows for expanding research. It supports future pipeline candidates. The company’s trajectory is set. It aims to deliver breakthrough cardiac treatments.
Secretome Therapeutics embodies cutting-edge biotechnology. Its nCPC platform represents a novel therapeutic modality. It targets complex biological pathways. Inflammation, fibrosis, and myocardial function are key. Addressing these simultaneously is critical for cardiac repair.
The future looks bright for Secretome Therapeutics. Their $30 million Series A funding provides substantial momentum. It paves the way for advanced clinical development. It strengthens their leadership. It reinforces their commitment to patients. Secretome is poised to make a profound difference in cardiac medicine.